HilleVax, Inc.
DelistedCIK 1888012fmd_1T8XW4WNFBQ7ANC0AWTBR2RV77Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2021 to Jun 30, 2025, 18 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Total operating expenses | 53 | 65 | 133 | 155 |
| Operating income | (53) | (65) | (133) | (155) |
| Interest expense | 3 | 3 | 2 | 3 |
| Interest and investment income | – | 4 | 10 | 7 |
| Other non-operating income (expense) | (49) | (95) | 10 | 8 |
| Net income | (102) | (160) | (124) | (147) |